BioRad to Buy DiaMed for $390M | GenomeWeb
NEW YORK (GenomeWeb News) - Bio-Rad said today it plans to buy reagent and screening tool-maker DiaMed Holding for around 477 million Swiss francs ($390 million).
 
The companies signed a definitive agreement under which Bio-Rad would buy 77.7 percent of DiaMed’s outstanding shares, after which Bio-Rad plans to conduct a tender offer buy nearly 13 percent of the remaining outstanding shares. The remaining 9.6 percent of DiaMed’s shares are treasury shares.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: genes involved in histone deacetylation in Arabidopsis, effects of pathogenic presenilin-1 mutations, and more.

After a study finds DNA from antibiotic-resistant bacteria in Beijing smog, residents there worry, according to the New York Times.

Canada begins its search for a chief government science advisor, Nature News reports.

A company is using facial recognition tools to identify genetic disorders from pictures, Technology Review reports.